Transjugular liver biopsy: enlarge the indications for liver biopsy with reliable diagnostic quality

BMC Gastroenterology

Table 3 Postoperative diagnosis analysis

Diagnosis	Before propensity score matching				After propensity score matching
Diagnosis	N (PLB/TJLB)	PLB	TJLB	P	N (PLB/TJLB)	PLB	TJLB	P
Etiology (%)	2711/30				50/25
Viral hepatitis		587 (21.7)	2 (6.7)	< 0.001		6 (12.0)	2 (8.0)	0.777
Autoimmune liver disease		849 (31.3)	10 (33.3)			16 (34.0)	9 (36.0)
ALD		60 (2.2)	2 (6.7)			3 (6.0)	2 (8.0)
Vascular liver disease		144 (5.3)	15 (50.0)			16 (32.0)	11 (44.0)
NAFLD		441 (16.3)	0 (0)			4 (8.0)	0 (0)
DILI		440 (16.2)	0 (0)			2 (4.0)	0 (0)
IMLD		65 (2.4)	0 (0)			0 (0)	0 (0)
Unknown		125 (4.6)	1 (3.3)			3 (6.0)	1 (4.0)
Diagnostic quality^a (%)	2124/28				44/23
success		1999 (94.1)	27 (96.4)	0.910		41 (93.2)	23 (95.7)	1.000
failed		125 (5.9)	1 (3.6)	0.910		3 (6.8)	1 (4.3)	1.000

Data are reported as number (percentage)
ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; DILI, drug-induced liver injury; IMLD, inherited metabolic liver disease
^a Diagnostic quality means that that the proportion of patients with a definite cause after liver biopsy, excluding those who had liver biopsy for definite viral hepatitis staging

ISSN: 1471-230X